David Sinclair

The evidence shows Sinclair has a clear and durable public vision centered on aging as a modifiable, potentially reversible biological process, with specific mechanisms including epigenetic reprogramming, biological clocks, lifestyle interventions, and cellular rejuvenation. The vision is ambitious and field-relevant, though the provided evidence is partly summarized rather than directly quoted from primary public statements, and some company-specific claims are only directionally supported.

The dimension applies, but the strongest required signal, citation metrics, appears misattributed: the OpenAlex block is labeled David Sinclair but describes Sheng Liu and lists unrelated engineering/materials papers. Using only reliable evidence here, Sinclair has primary evidence of authorship in aging biology, including a 2024 aging mouse gene-expression study and a 2025 Nature commentary, plus an unknown-independence bio claiming a Harvard genetics aging-research role. This supports real scientific activity, but not a field-defining impact score from the provided evidence.

The dimension applies because the evidence claims Sinclair founded a longevity-focused lab and co-founded longevity-related companies, which are institution-building activities. However, there is no disclosed personal investment, donation, fund allocation amount, or high-confidence evidence of capital deployed from his own resources, so the score remains low.

Strategic taste applies because the evidence shows repeated longevity-related institution and company formation, but the provided record does not establish a coherent thesis, early contrarian bet, counterfactual importance, stage preference, or rationale behind those choices. The strongest defensible signal is modest: founding or co-founding several organizations in the aging/longevity space suggests some institution-building orientation, but the evidence is too thin to credit high strategic judgment.

Field creation applies: the evidence says Sinclair founded or co-founded a lab and multiple longevity-related companies, which would make longevity work more organized and legible for others. However, the strongest field-creation claims are only supported by structured facts and an unknown-source investor dossier, with no primary or independent corroboration of the specific founding achievements, so the independence gate caps the score at 5.

The dimension applies because David Sinclair is a public longevity scientist and company founder, but the provided evidence contains almost no direct proof of bravery or conviction as defined by the rubric. The dossier supports public engagement in aging research and commercialization, yet there is no evidence here of contrarian risk-taking, career sacrifice, sustained criticism, large personal bets, or self-experimentation.

The dimension applies because the evidence shows repeated institution-building through Tally Health, Life Biosciences, and Sinclair Lab, plus public theory endorsement activity that could contribute to legitimacy around longevity concepts. However, the provided evidence does not directly show second-order outcomes such as attracted capital, recruited talent, policy influence, founder lineage, major collaborations, or follow-on projects beyond the organizations themselves.